Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ChIP-seq of H3K27ac and H3K27me3 in HSJD-DIPG-007 cell line upon treatment with ICG-001 and JQ1

ABSTRACT: Identification of super enhancer regions in the HSJD-DIPG-007 cell line and the associated genes with these regions. This study aims to evaluate the efficacy of combined use of BET and CBP inhibition in DIPG.

INSTRUMENT(S): Illumina HiSeq 4000

ORGANISM(S): Homo sapiens

SUBMITTER: Maria Wiese

PROVIDER: E-MTAB-9152 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq in HSJD-DIPG-007 cells treated with JQ1, ICG-001, JQ1 and ICG-001 and DMSO as control.

Project description:This study aims to characterize gene expression changes upon treatment with JQ1, ICG-001, and combined treatment. The general goal is to identify the mechanism for high efficacy of combinatorial treatment of BET and CBP inhibition in DIPG cells.

2020-08-01 | E-MTAB-8243 | biostudies-arrayexpress

ChIP-seq of H3K27ac and H3K27me3 in HSJD-DIPG-007 cell line

Project description:Identification of super enhancer regions in the HSJD-DIPG-007 cell line and the associated genes with these regions. This study aims to evaluate the efficacy of combined use of BET and CBP inhibition in DIPG.

2020-08-01 | E-MTAB-8242 | biostudies-arrayexpress

RNA-seq in HSJD-DIPG-007 cells treated with JQ1, ICG-001, JQ1 and ICG-001 and DMSO as control.

Project description:RNA-seq in HSJD-DIPG-007 cells treated with JQ1, ICG-001, JQ1 and ICG-001 and DMSO as control.

| PRJEB33971 | ENA

ChIP-seq of H3K27ac and H3K27me3 in HSJD-DIPG-007 cell line upon treatment with ICG-001 and JQ1

Project description:ChIP-seq of H3K27ac and H3K27me3 in HSJD-DIPG-007 cell line upon treatment with ICG-001 and JQ1

| PRJEB38635 | ENA

Gene expression (RNA-Seq) in pediatric high-grade glioma cell lines treated with selinexor and vehicle

Project description:Cultured pediatric high-grade glioma cell lines (SU-DIPG-IV, HSJD-DIPG-007, HSJD-GBM-001,BT 245 (RRID:CVCL_IP13)) were treated with selinexor (Karyopharm Therapeutics) at 5xIC50 for 16 hours or vehicle (0.1% DMSO) followed by bulk RNA-Seq

2020-01-06 | GSE137702 | GEO

The immunopeptidome and proteome of DIPG

Project description:DIPG is a devastating paediatric and young adult brainstem tumour with no cure and a median overall survival of 9 months. Cellular immunotherapy approaches require specific targeting of unique and tumour specific cell surface antigens, however, there is a paucity of known targets for DIPG. Here we used a proteomics platform approach to interrogate an array of patient derived DIPG cell lines to facilitate a multi-omics based approach to identify cell surface protein candidates enriched or unique to DIPG.

2023-09-25 | PXD038271 | Pride

PRMT5 inhibition by LLY-283 in HSJD-DIPG-007 DMG cells

Project description:PRMT5 inhibition by LLY-283 in HSJD-DIPG-007 DMG cells

| PRJNA957302 | ENA

PRMT5 inhibition by LLY-283 in HSJD-DIPG-007 DMG cells

Project description:H3K27-altered Diffuse Midline Glioma (DMG) is a universally fatal paediatric brainstem tumour. The prevalent driver mutation H3K27M creates a unique epigenetic landscape that may also establish therapeutic vulnerabilities to epigenetic inhibitors. From a wider screen of an epigenetic inhibitor library, we identified PRMT5 inhibitors as amongst the top hits reducing DMG cell viability. Here, we treated HSJD-DIPG-007 +/- the PRMT5 inhibitor LLY-283. RNA-sequencing was performed at 0, 1, 2, 3, 5, 7 and 10 days to assess the changes in gene expression following PRMT5 inhibition in DMG cells. This shows that PRMT5 inhibition changes expression in genes associated with multiple disease relevant phenotypes, including sterol metabolism, differentiation, and the extracellular matrix. By characterising the changes in the transcriptome following PRMT5 inhibition this provides crucial insights into the potential of PRMT5 inhibitors as a treatment for H3K27-altered DMG.

2024-01-05 | GSE230065 | GEO

Effect of CBL0137 on DIPG cells

Project description:Diffuse intrinsic pontine glioma (DIPG) is an aggressive and incurable childhood brain tumor for which new treatments are needed. A high throughput drug screen of 3600 pharmaceutical compounds found that anti-malarials, including quinacrine had potent activity against DIPG neurospheres. CBL0137 is a novel anti-cancer compound developed from quinacrine, which targets Facilitates Chromatin Transcription (FACT), a chromatin remodelling complex involved in transcription, replication, and DNA repair. We have found that CBL0137 displays profound cytotoxic activity against a panel of patient derived DIPG cultures, inhibiting cell proliferation and clonogenic potential, restoring tumor suppressor TP53 and Rb activity and inducing cell death through induction of apoptosis. Moreover, in an orthotopic model of DIPG, treatment with CBL0137 significantly extended animal survival. Histone mutations leading to the loss of histone trimethylation result in epigenetic dysregulation driving DIPG tumorigenesis. Treatment with CBL0137 targets this epigenetic defect, restoring both histone H3.3 acetylation and trimethylation and leading to tumor cell death. Combined epigenetic treatment with the histone deacetylase (HDAC) inhibitor panobinostat led to inhibition of the Rb/E2F1 pathway, and increased the enzymatic activity of enhancer of zeste homolog 2 (EZH2), leading to the restoration of H3K27 trimethylation. This combination therapy had synergistic activity against DIPG neurospheres with induction of apoptosis. Consistent with the in vitro results, the combination of CBL0137 and panobinostat significantly prolonged the survival of mice bearing DIPG orthografts suggesting a potential treatment strategy for DIPG.

2021-03-07 | GSE153883 | GEO

ChIP-seq of H3K27ac and H3K27me3 in HSJD-DIPG-007 cell line

Project description:ChIP-seq of H3K27ac and H3K27me3 in HSJD-DIPG-007 cell line

| PRJEB33970 | ENA